The relationship between vancomycin tolerance and clinical outcomes in patients with Staphylococcus aureus bacteremia
Issue Date
2014-05-31Author
Britt, Nicholas
Publisher
University of Kansas
Format
23 pages
Type
Thesis
Degree Level
M.S.
Discipline
Clinical Research
Rights
Copyright held by the author.
Metadata
Show full item recordAbstract
Background: Treatment failure is increasingly common in Staphylococcus aureus bacteremia (SAB). Vancomycin tolerance may be playing a role in clinical outcomes in SAB that has yet to be fully explored. Methods: This was a single-center retrospective cohort study of 166 patients (September 2012 - January 2014) evaluating the relationship between vancomycin tolerance and clinical failure in SAB. Vancomycin minimum inhibitory concentration (MIC) was determined by broth microdilution and Etest. Vancomycin tolerance was defined as a vancomycin minimum bactericidal concentration (MBC)/MIC greater than or equal to 32. Univariable and multivariable analyses were conducted to determine the relationship between vancomycin tolerance and clinical failure after adjusting for other factors. Results: Of the 166 patients evaluated, 26.5% had vancomycin tolerant clinical isolates. Tolerance to vancomycin was more common in methicillin-susceptible S. aureus bacteremia (MSSA-B) than methicillin-resistant S. aureus bacteremia (MRSA-B; n=29/101 [28.7%] vs. n=15/65 [23.1%]), although not significantly (P=0.422). Clinical failure was frequently observed (50% overall). Elevated vancomycin MIC by Etest (greater than or equal to 1.5 mcg/mL) was not associated with clinical failure (P=0.50). Vancomycin tolerance was significantly associated with SAB clinical failure in univariable analysis (P=0.014). This relationship persisted even when adjusting for other factors in multivariable analysis (adjusted odds ratio [AOR], 2.70; 95% confidence interval [CI], 1.27-5.70; P=0.010). Conclusions: Vancomycin tolerance is a clinically significant predictor of clinical failure in SAB independent of methicillin susceptibility and antibiotic choice. Future research is needed to determine optimal treatment of vancomycin tolerant SAB.
Collections
- KU Med Center Dissertations and Theses [464]
- Theses [3901]
Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.